Comparison

MHI Thermal Systems Adds New KXZ3 Series of Building-use Multi-Split Air- Conditioners Adopting R32 Refrigerant

Retrieved on: 
tisdag, april 9, 2024
Mitsubishi Heavy Industries, MHI, Safety, Temperature, GWP, Heat, Carbon, Note 2, Comparison, R32

The newly added lineup, which adopts the R32 refrigerant, is available in three models: 22.4, 28.0 and 33.5kW.

Key Points: 
  • The newly added lineup, which adopts the R32 refrigerant, is available in three models: 22.4, 28.0 and 33.5kW.
  • The new series will be launched in the European market this summer, to be followed by successive launches in Australia, New Zealand and Turkey.
  • The KXZ3 Series helps mitigate environmental impacts through adoption of the R32 refrigerant having a Global Warming Potential (GWP) (Note1) of 675, which is roughly one-third the level of the R410A refrigerant (GWP 2,090) used in earlier models.
  • Under certain conditions, the KXZ3 Series, like other products adopting the R32 refrigerant, also requires additional safety features in order to satisfy European safety standards.

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

Retrieved on: 
torsdag, maj 9, 2024
University, OAT, Political moderate, Splint (medicine), ENT, CPAP, University of Antwerp, MD, Research, First Line, Dentist, Continuous positive airway pressure, Obstructive sleep apnea, Sleep apnea, Telehealth, Faculty, AHI, Comparison, OSA, Neuroscience, Pharmaceutical industry

1Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 2Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.

Key Points: 
  • 1Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 2Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.
  • The data from the FLOSAT study indicate that OSA therapy with ProSomnus EVO devices is safe, effective, and better adhered to than CPAP.
  • BlueSleep, the leader in virtual diagnosis and treatment of sleep apnea, is presenting results of two studies at the 2024 AADSM Annual Meeting.
  • In a second study, BlueSleep compared the initial fitting of ProSomnus devices either in a virtual or in-person workflow.

CytoSorbents Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
Sale, Travel, Research, ATM, Comparison, Marketing, Advertising, Clinical trial, Currency

For additional information, please see the Company’s Form 10-Q for the period ended March 31, 2024, filed on May 9, 2024, on http://www.sec.gov .

Key Points: 
  • For additional information, please see the Company’s Form 10-Q for the period ended March 31, 2024, filed on May 9, 2024, on http://www.sec.gov .
  • For the three months ended March 31, 2024, and 2023, cost of revenue was approximately $3,216,000 and $3,994,000, respectively, a decrease of approximately $778,000.
  • Product gross margins were approximately 76% during the three months ended March 31, 2024 (which excludes the impact of a one-time, non-recurring inventory adjustment of approximately $304,000 recorded in the first quarter of 2024), as compared to 68% during the three months ended March 31, 2023.
  • We believe this is sufficient to fund the Company’s operations into the fourth quarter of 2024.

NewLake Capital Partners Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Common, Tenant, Conference, TIS, Growth, FFO, Cannabis, Comparison, TI, Holding company

NEW CANAAN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OCTQX: NLCP) (the “Company” or “NewLake”), a leading provider of real estate capital to state-licensed cannabis operators, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • First Quarter 2024 Revenue Totaled $12.6 Million, an increase of 10.4% Year-Over-Year
    First Quarter 2024 Net Income Attributable to Common Stockholders Totaled $6.9 Million, Funds from Operations Totaled $10.6 Million, and Adjusted Funds from Operations Totaled $11.0 Million
    Conference Call and Webcast Scheduled for May 9, 2024, at 11 a.m. Eastern Time
    NEW CANAAN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OCTQX: NLCP) (the “Company” or “NewLake”), a leading provider of real estate capital to state-licensed cannabis operators, today announced its financial results for the first quarter ended March 31, 2024.
  • Anthony Coniglio, President and Chief Executive Officer, said, “We are pleased with the performance of our portfolio and financial results during the first quarter of 2024.
  • As a result, presented below reflects only the first quarter financial results.
  • Comparison to the first quarter ended March 31, 2023:
    Quarterly year-over-year financial results were impacted by the non-payment of contractual rent from one tenant in 2023.

First Federal Savings Bank and ICBA Offer Tips for Graduates to Secure Their Financial Future

Retrieved on: 
onsdag, maj 8, 2024
Spend, Workforce, Independent, Negotiation, Retirement, Student, Comparison, ICBA, Bank

EVANSVILLE, Ind., May 08, 2024 (GLOBE NEWSWIRE) -- As students prepare to transition into the workforce, First Federal Savings Bank, and the Independent Community Bankers of America (ICBA), are providing tips to put them on the path to a prosperous financial future.

Key Points: 
  • EVANSVILLE, Ind., May 08, 2024 (GLOBE NEWSWIRE) -- As students prepare to transition into the workforce, First Federal Savings Bank, and the Independent Community Bankers of America (ICBA), are providing tips to put them on the path to a prosperous financial future.
  • Marketing Manager at First Federal Savings Bank.
  • “As your trusted financial advisor, First Federal Savings Bank can help you take stock of your financial situation and create a blueprint based on your unique circumstances and life goals to help you establish financial independence.”
    First Federal Savings Bank and ICBA offer the following tips to help graduates create a financial gameplan during their wealth-building years to set them up for success through their major financial lifecycle events:
    Start a budget.
  • “Reach out to your local community banker to create an action plan to put your finances to work to help ensure your prosperous financial future.”

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Retrieved on: 
tisdag, maj 7, 2024
Patient, Safety, SAN, Poster, Abstract, Kyowa Kirin, Cell, NOD2, Transplant, Hurler syndrome, POC, Skeleton, Gene, Society, Comparison, HSC, Atidarsagene autotemcel, MLD, Therapy, Communications satellite

TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore.

Key Points: 
  • TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore.
  • In addition, Orchard Therapeutics will give an invited oral presentation highlighting the potential of OTL-104, a pre-clinical HSC gene therapy developed by its in-house research team, to address a severe and treatment refractory form of Crohn’s disease.
  • “Our presentations at ASGCT add to the compendium of evidence supporting the transformative impact and broad applicability of our approach,” said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
  • Title: Non-neurological, Non-Skeletal Outcomes After Autologous Hematopoietic Stem Cell Gene therapy in Hurler Patients: Retrospective Comparison with Allogeneic Hematopoietic Stem Cell Transplantation​
    Date/Time: Friday, May 10 from noon to 1:30 p.m. and from 5:30 to 7:00 p.m.
    Date/Time: Friday, May 10 from noon to 1:30 p.m. and from 5:30 to 7:00 p.m.

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

Retrieved on: 
torsdag, maj 9, 2024
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Congress, Glucocorticoid, Safety, Patient, Kidney, Lupus nephritis, Proteinuria, CNI, EULAR, Rheumatology, Steroid, Cyclophosphamide, Comparison, CCR, Standard of care, MMF, Pharmaceutical industry

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12.
  • The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program.
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the AURA-LV plus AURORA 1 studies were assessed at three and six months.
  • “Early reduction in proteinuria after initial treatment has been associated with improved long-term kidney outcomes in lupus nephritis,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia.

HASI Announces First Quarter 2024 Results, Establishes $2b Strategic Partnership with KKR

Retrieved on: 
tisdag, maj 7, 2024
Environment, Finance, Banking, Professional Services, Alternative Energy, Green Technology, Energy, Socially Responsible Investing, Asset Management, Sale, Rotation, Investment, GAAP, Growth, HASI, Comparison, Bank

Interest expense increased $25 million primarily due to a larger average outstanding debt balance and a higher average interest rate.

Key Points: 
  • Interest expense increased $25 million primarily due to a larger average outstanding debt balance and a higher average interest rate.
  • We recorded a $2 million provision for loss on receivables and securitization assets as a result of loans and loan commitments made during the quarter.
  • GAAP net income (loss) to controlling shareholders in the first quarter of 2024 was $123 million, compared to $24 million in the same period in 2023.
  • The calculation of our fixed-rate debt and leverage ratios as of March 31, 2024 and December 31, 2023 are shown in the table below:

Cranium Introduces First-of-Its-Kind Exposure Management Solution for AI & GenAI

Retrieved on: 
måndag, maj 6, 2024
Organization, OODA, RSA Conference, LLM, Machine learning, Conference, Intelligence, Comparison, Privacy, RSAC, Architecture, Medical device

SHORT HILLS, N.J., May 6, 2024 /PRNewswire/ -- Cranium , the leading enterprise AI security and trust software firm, today announced it launched Cranium AI Exposure Management, the first exposure management solution to help organizations protect and secure internal and third-party AI solutions.

Key Points: 
  • SHORT HILLS, N.J., May 6, 2024 /PRNewswire/ -- Cranium , the leading enterprise AI security and trust software firm, today announced it launched Cranium AI Exposure Management, the first exposure management solution to help organizations protect and secure internal and third-party AI solutions.
  • Cranium AI Exposure Management enables AI red-teaming in each phase of the OODA loop:
    Observe: Map and characterize the AI attack surface.
  • Key features of Cranium's AI Exposure Management solution include:
    Establish a robust framework for safely integrating AI capabilities throughout business operations.
  • For more information about Cranium AI Exposure Management, please visit https://www.cranium.ai/ or click here to schedule a demo .

Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the First Quarter of 2024

Retrieved on: 
torsdag, maj 2, 2024
Sale, Chunghwa Telecom, Prospectus, International, Artificial intelligence of things, Internet of things, ICT, ARPU, Depreciation, Yoy, Carbon, Financial Supervisory Commission, Comparison, Forecasting, Income tax, CHT, EPS, F-3, Bank statement, Growth, TAIEX, Bank

TAIPEI, May 2, 2024 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the first quarter of 2024.

Key Points: 
  • TAIPEI, May 2, 2024 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the first quarter of 2024.
  • Our robust first quarter results have once again showcased the efficacy of our strategic execution and the excellence of our dedicated team," stated Mr. Shui-Yi Kuo, Chairman and CEO of Chunghwa Telecom.
  • Chunghwa Telecom's total revenues for the first quarter of 2024 increased by 1.4% to NT$ 54.94 billion.
  • In addition to the consolidated financial results prepared under T-IFRSs, Chunghwa Telecom also provide non-GAAP financial measures, including "EBITDA".